BBK Worldwide Launches Online Purchasing of Scalable Recruitment Services
BBK Worldwide has launched shop.BBKWorldwide.com, an online resource where clinical research professionals can go to learn about, and purchase, a full range of patient recruitment products and services. The website not only redefines the purchasing process by fostering more timely and informed decisions, but it redefines the audience of purchasers to include those looking for quick, stand-alone solutions.
"In an industry driven by the pressure to reduce time-to-market, traditional strategies have focused on accelerating the enrollment of patients," comments Bonnie A. Brescia, founding principal, BBK Worldwide. "We're looking to influence timelines even sooner – during the purchasing phase, when valuable time can be lost identifying and learning about the latest solutions. With shop.BBKWorldwide.com, customers can now get a jumpstart assessing products and services, allowing for quicker and more informed decisions."
"With more complex clinical trials comes the demand for more advanced tools," comments Joan F. Bachenheimer, founding principal and CEO, BBK Worldwide. "BBK has a strong commitment to not only provide innovative and cost-effective solutions, but to provide them in a way that educates and advances the industry at-large."
shop.BBKWorldwide.com redefines the typical consumer. Clinical trial sponsors who previously may not have considered purchasing patient recruitment services now have an affordable and scalable way to do so. In addition to time-tested full-service solutions, the site features a range of recent innovations that include:
Ready. Set. Go. Card(SM) – a quick and convenient way to provide global study reimbursements.
Clinical Study Notifier(SM) – a notification service that alerts patients to clinical trials.
eBinder: Study iPads® – a communication platform that makes it easy to manage documents, data, and study personnel across multiple sites, clinical teams, and continents.
"shop.BBKWorldwide.com represents a major shift in how clinical research professionals can learn about and purchase products and services. In addition, the website provides a significant benefit to sponsors' in-house specialists who are responsible for understanding and managing recruitment resources," comments Bachenheimer. "It's a game-changer. Within two to three years, the industry should demand this to be the norm."
shop.BBKWorldwide.com will be launched at the 48th Annual Meeting of the Drug Information Association, 24–28 June, 2012, in Philadelphia.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
